A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2018
At a glance
- Drugs ABBV 368 (Primary) ; Nivolumab
- Indications Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 28 Feb 2018 Planned End Date changed from 16 Oct 2019 to 26 Feb 2020.
- 31 Oct 2017 Planned End Date changed from 27 Oct 2019 to 16 Oct 2019.
- 31 May 2017 Planned number of patients changed from 180 to 100.